

August 22, 1967

Dr. Charles J. Dunn, Jr.  
Associate Medical Director  
Endo Laboratories, Inc.  
1000 Stewart Avenue  
Garden City, New York 11533

Dear Dr. Dunn:

Please excuse the delay in answering your letter of July 6, but the holidays intervened and I was not able to review the data on Molindone until this week. I found Dr. Sugerman's report of great interest and believe that a comparative study with a standard antipsychotic drug is probably needed at present.

Unfortunately, we do not have a population at Metropolitan Hospital suitable for such a study.

For this reason, I would suggest that you contact my former associate, Dr. Turan Itil, at the Missouri Institute of Psychiatry. He has studied a number of novel compounds using both clinical and EEG analyses and has available to him a population of severe mentally ill. I am taking the liberty of sending him a carbon of this letter in the hope that this will expedite your communication with him, if you wish.

Thank you very much for the opportunity to read the literature on this compound.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp

enc.